UA82983C2 - Полимерные коньюгаты найбластина и способы их использования - Google Patents

Полимерные коньюгаты найбластина и способы их использования

Info

Publication number
UA82983C2
UA82983C2 UA2003088104A UA2003088104A UA82983C2 UA 82983 C2 UA82983 C2 UA 82983C2 UA 2003088104 A UA2003088104 A UA 2003088104A UA 2003088104 A UA2003088104 A UA 2003088104A UA 82983 C2 UA82983 C2 UA 82983C2
Authority
UA
Ukraine
Prior art keywords
neublastin
methods
same
polymer conjugates
conjugate
Prior art date
Application number
UA2003088104A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дінах В.У. Сах
Р. Блейк Пепінскі
Паула Енн Борджек-С'єдін
Стефан С. Міллєр
Ентоні Россомандо
Original Assignee
Байоджен Айдек Ма Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Ма Інк. filed Critical Байоджен Айдек Ма Інк.
Publication of UA82983C2 publication Critical patent/UA82983C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Заявлен полипептид нейбластина, пригодный для образования коньюгата, который содержит полипептид нейбластина, связанный с полимером, который содержит полиалкиленгликолевый компонент. Данный коньюгат имеет пролонгированную биодоступность по сравнению с немодифицированными формами или формами дикого типа нейбластина. Коньюгаты согласно изобретению имеют полезное применение при терапевтическом, а также диагностическом, использовании.
UA2003088104A 2001-02-01 2002-01-25 Полимерные коньюгаты найбластина и способы их использования UA82983C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01

Publications (1)

Publication Number Publication Date
UA82983C2 true UA82983C2 (ru) 2008-06-10

Family

ID=23013042

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200802148A UA100967C2 (ru) 2001-02-01 2002-01-25 Конъюгаты нейбластина с полимерами и способы их применения
UA2003088104A UA82983C2 (ru) 2001-02-01 2002-01-25 Полимерные коньюгаты найбластина и способы их использования

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA200802148A UA100967C2 (ru) 2001-02-01 2002-01-25 Конъюгаты нейбластина с полимерами и способы их применения

Country Status (36)

Country Link
EP (2) EP1862475A1 (ru)
JP (2) JP4259868B2 (ru)
KR (2) KR100960063B1 (ru)
CN (1) CN1500095B (ru)
AR (1) AR035077A1 (ru)
AT (1) ATE365748T1 (ru)
AU (1) AU2002247037B2 (ru)
BG (1) BG66393B1 (ru)
BR (1) BR0206852A (ru)
CA (1) CA2436407C (ru)
CY (1) CY1106886T1 (ru)
CZ (1) CZ20032080A3 (ru)
DE (1) DE60220879T2 (ru)
DK (1) DK1355936T3 (ru)
EA (1) EA009771B1 (ru)
EE (1) EE05537B1 (ru)
ES (1) ES2289091T3 (ru)
GE (1) GEP20063916B (ru)
HK (1) HK1057759A1 (ru)
HU (1) HU228973B1 (ru)
IL (2) IL156941A0 (ru)
IS (1) IS2867B (ru)
MX (1) MXPA03006805A (ru)
MY (1) MY143685A (ru)
NO (1) NO332150B1 (ru)
NZ (1) NZ527863A (ru)
PL (1) PL211162B1 (ru)
PT (1) PT1355936E (ru)
RS (1) RS50857B (ru)
SG (1) SG149685A1 (ru)
SI (1) SI1355936T1 (ru)
SK (1) SK288123B6 (ru)
TR (1) TR200301208T2 (ru)
UA (2) UA100967C2 (ru)
WO (1) WO2002060929A2 (ru)
ZA (1) ZA200305733B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289091T3 (es) * 2001-02-01 2008-02-01 Biogen Idec Ma Inc. Conjugados polimeros de neublastina y metodos para usar los mismos.
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
JP4499362B2 (ja) * 2001-03-28 2010-07-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューロパシーの疼痛を処置するためのニューブラスチンポリペプチドの使用
DK3025726T3 (da) * 2002-01-18 2019-12-09 Biogen Ma Inc Polyalkylenpolymerforbindelser og anvendelser deraf
RS52910B (en) * 2003-01-31 2014-02-28 Biogen Idec Ma Inc. POLYMER CONJUGATES OF MUTATED NEUBLASTINE
EP2322205A1 (en) 2003-04-18 2011-05-18 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
DK1636260T3 (da) 2003-06-10 2009-06-22 Biogen Idec Inc Forbedret udskillelse af Neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CA2577755C (en) 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Neublastin variants
DE602005022082D1 (de) * 2004-08-19 2010-08-12 Biogen Idec Inc Rückfaltung von proteinen der transforming-growth-factor-beta-familie
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
AU2007296843C1 (en) 2006-09-15 2012-08-16 Creabilis Therapeutics S.P.A. Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
DK2773438T4 (da) * 2011-11-02 2022-01-03 Hoffmann La Roche Overladnings- og elueringskromatografi
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
EP1137774A2 (en) * 1998-12-09 2001-10-04 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
ES2289091T3 (es) * 2001-02-01 2008-02-01 Biogen Idec Ma Inc. Conjugados polimeros de neublastina y metodos para usar los mismos.

Also Published As

Publication number Publication date
IS6879A (is) 2003-07-17
MY143685A (en) 2011-06-30
KR20030074766A (ko) 2003-09-19
ZA200305733B (en) 2005-02-23
CN1500095B (zh) 2010-06-16
SK9712003A3 (en) 2004-01-08
CN1500095A (zh) 2004-05-26
BR0206852A (pt) 2005-05-03
CY1106886T1 (el) 2012-09-26
EP1355936A2 (en) 2003-10-29
YU61003A (sh) 2006-05-25
GEP20063916B (en) 2006-09-11
JP4259868B2 (ja) 2009-04-30
EA009771B1 (ru) 2008-04-28
EE05537B1 (et) 2012-04-16
EA200300852A1 (ru) 2004-06-24
CA2436407C (en) 2011-08-30
HUP0500637A3 (en) 2010-01-28
WO2002060929A2 (en) 2002-08-08
PT1355936E (pt) 2007-09-28
DK1355936T3 (da) 2007-10-29
KR20080098662A (ko) 2008-11-11
IS2867B (is) 2014-02-15
BG66393B1 (bg) 2013-11-29
ES2289091T3 (es) 2008-02-01
DE60220879T2 (de) 2008-03-06
KR100872807B1 (ko) 2008-12-09
NO332150B1 (no) 2012-07-09
MXPA03006805A (es) 2003-11-13
JP4423338B2 (ja) 2010-03-03
UA100967C2 (ru) 2013-02-25
ATE365748T1 (de) 2007-07-15
IL156941A (en) 2008-11-03
IL156941A0 (en) 2004-02-08
RS50857B (sr) 2010-08-31
SG149685A1 (en) 2009-02-27
AU2002247037B2 (en) 2007-08-16
BG108111A (bg) 2004-12-30
JP2005503763A (ja) 2005-02-10
HUP0500637A2 (hu) 2005-09-28
SK288123B6 (sk) 2013-09-03
AR035077A1 (es) 2004-04-14
HK1057759A1 (en) 2004-04-16
CZ20032080A3 (cs) 2003-10-15
DE60220879D1 (de) 2007-08-09
HU228973B1 (en) 2013-07-29
TR200301208T2 (tr) 2005-05-23
PL211162B1 (pl) 2012-04-30
PL372101A1 (en) 2005-07-11
WO2002060929A3 (en) 2003-03-06
KR100960063B1 (ko) 2010-05-31
NO20033441D0 (no) 2003-08-01
CA2436407A1 (en) 2002-08-08
JP2009039135A (ja) 2009-02-26
NZ527863A (en) 2006-09-29
EP1355936B1 (en) 2007-06-27
EP1862475A1 (en) 2007-12-05
EE200300355A (et) 2003-10-15
SI1355936T1 (sl) 2007-12-31
NO20033441L (no) 2003-10-01

Similar Documents

Publication Publication Date Title
UA82983C2 (ru) Полимерные коньюгаты найбластина и способы их использования
RS20050263A (en) Polymer conjugates with decreased antigenicity,methods of preparation and uses thereof
MXPA04001982A (es) Factor ix modificado.
EP2353611A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1196444B8 (en) Exendin-4 conjugates and their medical use
MXPA03011094A (es) Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
SG159381A1 (en) Remodeling and glycoconjugation of peptides
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
WO2004005326A3 (de) Tubulysinkonjugate
WO2004075923A3 (en) Polymer-factor viii moiety conjugates
WO2001068145A3 (en) Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
WO2003037384A3 (en) Polymer conjugates of protein kinase c inhibitors
MXPA03011282A (es) Mezclas de conjugados de farmaco de hormona de crecimiento-oligomero que comprenden polialquilenglicol, uso de los mismos y metodos para su elaboracion.
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU2002215904A1 (en) Compounds with a branched linker
WO2003049699A3 (en) Novel monofunctional polyethylene glycol aldehydes
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
PL366692A1 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
EP1607399A3 (en) BIS-(N,N'-BIS-(2-Haloethyl)Amino) Phosphoramidates as antitumor agents
WO2005058421A3 (en) Use of a compound having two gold (i) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold (i) atoms for the treatment of cancer
AU2001238470A1 (en) 9-alkylamino-1-nitroacridine derivatives
AU2002354872A1 (en) Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents